Immune-mediated blood disorders:
Indications for RHOGAM:
Preventing Rho(D) sensitization in nonsensitized Rho(D) negative or Du negative patients to the Rho(D) factor, following pregnancy or accidental transfusion.
Each vial or syringe (approx. 300mcg) prevents sensitization to a volume of up to 15mL of Rh positive red blood cells. Administer IM at 28 weeks of gestation, within 72 hours of an Rh incompatible delivery, miscarriage, abortion, or transfusion accident.
Rho(D) positive patients.
Single-dose syringes—5, 25